Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 53,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "87187f3c-57ed-486f-b97f-ca5033a77512",
"title": "Wall Street Brunch: All Aboard The Earnings Train",
"description": "JPMorgan, Citi, BofA, Wells Fargo, Goldman and more on the calendar. Hot CPI could slash odds of rate cuts further. L.A. wildfires could be most costly ever.",
"keywords": "",
"snippet": "EschCollection/DigitalVision via Getty Images\n\nListen below or on the go on Apple Podcasts and Spotify\n\nJPMorgan, Citi, BofA, Wells Fargo, Goldman and more on t...",
"url": "https://seekingalpha.com/article/4748990-wall-street-brunch-all-aboard-the-earnings-train",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2169900738/image_2169900738.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-01-12T19:11:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ABT",
"name": "Abbott Laboratories",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.875488,
"sentiment_score": 0,
"highlights": [
{
"highlight": "For income investors, companies with an [+186 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "92902653-ee48-404a-a136-bdb864b008e0",
"title": "QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase",
"description": "QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shar",
"keywords": "GuruFocus, Article, News, Business Wire, NYSE:QGEN",
"snippet": "QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to share...",
"url": "https://www.gurufocus.com/news/2653453/qiagen-to-return-approximately-300-million-to-shareholders-through-a-synthetic-share-repurchase",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-01-12T19:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "QIA.DE",
"name": "QIAGEN N.V.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 56.030735,
"sentiment_score": 0.52059,
"highlights": [
{
"highlight": "<em>QIAGEN</em> <em>N.V</em>. (NYSE: QGE[+251 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "This new repurchase comes after <em>QIAG[+272 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> has decided to implement[+178 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "“<em>QIAGEN</em> has a proven track re[+237 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Roland Sackers, Chief Financial Officer [+292 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>QIAGEN</em>\n\n<em>QIAGEN</em> <[+329 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> provides solutions to mo[+283 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "fluctuations in demand for QIAGEN's prod[+335 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "For further information, please refer to[+286 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "QGEN",
"name": "QIAGEN N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 70.41877,
"sentiment_score": 0.52059,
"highlights": [
{
"highlight": "<em>QIAGEN</em> <em>N.V</em>. (<em>NYSE<[+269 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "This new repurchase comes after <em>QIAG[+272 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> has decided to implement[+178 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "“<em>QIAGEN</em> has a proven track re[+237 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Roland Sackers, Chief Financial Officer [+292 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>QIAGEN</em>\n\n<em>QIAGEN</em> <[+329 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> provides solutions to mo[+283 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "fluctuations in demand for QIAGEN's prod[+335 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "For further information, please refer to[+286 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "604c5821-6b92-49f5-b711-29d5c38ecb8c",
"title": "QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase By Investing.com",
"description": "QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase",
"keywords": "",
"snippet": "Capital return to be conducted through synthetic share repurchase “ combines a fast direct capital repayment to shareholders with a reverse stock split that e...",
"url": "https://www.investing.com/news/press-releases/qiagen-to-return-approximately-300-million-to-shareholders-through-a-synthetic-share-repurchase-93CH-3808222",
"image_url": "https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png",
"language": "en",
"published_at": "2025-01-12T18:08:03.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "QGEN",
"name": "QIAGEN N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 68.91127,
"sentiment_score": 0.397264,
"highlights": [
{
"highlight": "<em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NYSE</em>: <em>QGEN</em>; Frankfurt[+239 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "This new repurchase comes after <em>QIAG[+272 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> has decided to implement[+178 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> has a proven track recor[+231 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Roland Sackers, Chief Financial Officer [+289 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>QIAGEN</em>\n\n<em>QIAGEN</em> <[+329 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> provides solutions to mo[+283 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "For further information, please refer to[+165 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Source: <em>QIAGEN</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase By Investing.com",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "QIA.DE",
"name": "QIAGEN N.V.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.551025,
"sentiment_score": 0.430327,
"highlights": [
{
"highlight": "shareholders with a reverse stock split [+329 characters]",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "This new repurchase comes after <em>QIAG[+272 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> has decided to implement[+178 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> has a proven track recor[+231 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Roland Sackers, Chief Financial Officer [+289 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>QIAGEN</em>\n\n<em>QIAGEN</em> <[+329 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> provides solutions to mo[+283 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "For further information, please refer to[+165 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Source: <em>QIAGEN</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase By Investing.com",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "dcf56353-ecd3-4db2-9993-2dede8b3fc84",
"title": "IDEAYA Biosciences Announces Strategic Updates at J.P. Morgan Healthcare Conference",
"description": "Summary IDEAYA Biosciences Inc (IDYA), a leader in precision medicine oncology, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference",
"keywords": "GuruFocus, Article, News, GuruFocus News, IDYA",
"snippet": "Summary\n\nIDEAYA Biosciences Inc (IDYA, Financial), a leader in precision medicine oncology, announced its participation in the 43rd Annual J.P. Morgan Healthcar...",
"url": "https://www.gurufocus.com/news/2653452/ideaya-biosciences-announces-strategic-updates-at-jp-morgan-healthcare-conference",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-01-12T18:02:26.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IDYA",
"name": "IDEAYA Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 91.709435,
"sentiment_score": 0.37808,
"highlights": [
{
"highlight": "Summary\n\n<em>IDEAYA</em> <em>Biosciences[+180 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+296 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nAs [+187 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "FAQ\n\nQ: What is <em>IDEAYA</em> <em>Bios[+247 characters]",
"sentiment": 0.3736,
"highlighted_in": "main_text"
},
{
"highlight": "<em>IDEAYA</em> <em>Biosciences</em> Announces Strategic Updates at J.P. Morgan Healthcare Conference",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "f8196cb9-3ae0-48fb-9619-7b4f9a6d7b41",
"title": "IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance",
"description": "PR NewswireSOUTH SAN FRANCISCO, Calif., Jan. 12, 2025\n\n\n\nSOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a",
"keywords": "GuruFocus, Article, News, PRNewswire, NAS:IDYA",
"snippet": "SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the disco...",
"url": "https://www.gurufocus.com/news/2653451/ideaya-biosciences-announces-participation-at-the-43rd-annual-jp-morgan-healthcare-conference-and-2025-corporate-guidance",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-01-12T18:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IDYA",
"name": "IDEAYA Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 96.39047,
"sentiment_score": 0.1441,
"highlights": [
{
"highlight": "., Jan. 12, 2025 /PRNewswire/ -- <em>IDE[+342 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Hata , Chief Executive Officer, <em>IDEA[+214 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>IDEAYA</em> <em>Biosciences</e[+181 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Investor and Media Contact\n\n<em>IDEAYA</[+354 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "-302348559.html\n\nSOURCE <em>IDEAYA</em> [+35 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>IDEAYA</em> <em>Biosciences</em> Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "54e68bd6-e1b6-4d43-bcee-6ffd518075d8",
"title": "Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference",
"description": "Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipel",
"keywords": "GuruFocus, Article, News, Marketwired, MOLN",
"snippet": "Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025\n\nMesothelin named as second target in Radio-DARPin pip...",
"url": "https://www.gurufocus.com/news/2653450/molecular-partners-outlines-clinical-expansion-plans-and-strengthens-radiopharma-strategic-focus-for-2025-at-43rd-annual-jp-morgan-healthcare-conference",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-01-12T18:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MLLCF",
"name": "Molecular Partners AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.815346,
"sentiment_score": 0.223027,
"highlights": [
{
"highlight": "., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad [+365 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> has[+122 characters]",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Presentation Details:\n\nPresenter:[+289 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Partners</e[+248 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> lev[+299 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Some of the key factors that could cause[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "for its product candidates; the extent o[+375 characters]",
"sentiment": -0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "; the impact of any health pandemic, mac[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "and manufacturing capabilities and strat[+372 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "set forth in <em>Molecular</em> <em>Part[+169 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference",
"sentiment": 0.4588,
"highlighted_in": "title"
}
]
},
{
"symbol": "MOLN.SW",
"name": "Molecular Partners AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.811314,
"sentiment_score": 0.223027,
"highlights": [
{
"highlight": "., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad [+365 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> has[+122 characters]",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Presentation Details:\n\nPresenter:[+289 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Partners</e[+248 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> lev[+299 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Some of the key factors that could cause[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "for its product candidates; the extent o[+375 characters]",
"sentiment": -0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "; the impact of any health pandemic, mac[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "and manufacturing capabilities and strat[+372 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "set forth in <em>Molecular</em> <em>Part[+169 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference",
"sentiment": 0.4588,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "ec1212f4-1e52-4aef-8bf0-07c6e8c354cf",
"title": "Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer",
"description": "New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenEx",
"keywords": "GuruFocus, Article, News, Marketwired, MOLN",
"snippet": "New agreement enables both companies to fuel a broad and innovative pipeline of 212 Pb-Radio-DARPin candidates, bringing the total number of programs up to ten\n...",
"url": "https://www.gurufocus.com/news/2653449/molecular-partners-and-orano-med-expand-partnership-to-develop-targeted-alpha-radiotherapies-for-cancer",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-01-12T18:00:01.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MLLCF",
"name": "Molecular Partners AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.422497,
"sentiment_score": 0.143982,
"highlights": [
{
"highlight": "and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE[+340 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> wil[+312 characters]",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Partners</e[+348 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> lev[+299 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "For further details, please contact:\n\n<e[+111 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Some of the key factors that could cause[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "for its product candidates; the extent o[+375 characters]",
"sentiment": -0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "; the impact of any health pandemic, mac[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "and manufacturing capabilities and strat[+372 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "that are described in the Risk Factors s[+266 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer",
"sentiment": -0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "MOLN.SW",
"name": "Molecular Partners AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.417763,
"sentiment_score": 0.143982,
"highlights": [
{
"highlight": "and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE[+340 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> wil[+312 characters]",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Partners</e[+348 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> lev[+299 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "For further details, please contact:\n\n<e[+111 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Some of the key factors that could cause[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "for its product candidates; the extent o[+375 characters]",
"sentiment": -0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "; the impact of any health pandemic, mac[+374 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "and manufacturing capabilities and strat[+372 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "that are described in the Risk Factors s[+266 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Partners</em> and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer",
"sentiment": -0.4767,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b9f2e79c-fe88-4721-8815-e0d52b9a09f5",
"title": "QIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück",
"description": "EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf\nQIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen...",
"keywords": "it-times, Internet, aktuelle Informationen, Telekommunikation, Telko, Halbleiter",
"snippet": "EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf\n\nQIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine...",
"url": "https://www.it-times.de/news/qiagen-n-v-qiagen-zahlt-rund-300-millionen-dollar-durch-einen-synthetischen-aktienrueckkauf-an-seine-aktionaerinnen-und-aktionaere-zurueck-167569/",
"image_url": "https://www.it-times.de/resources/dam/asset/25013/social_networks.jpg",
"language": "de",
"published_at": "2025-01-12T17:55:45.000000Z",
"source": "it-times.de",
"relevance_score": null,
"entities": [
{
"symbol": "QGEN",
"name": "QIAGEN N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 94.96765,
"sentiment_score": null,
"highlights": [
{
"highlight": "EQS-Ad-hoc: <em>QIAGEN</em> <em>N.V</em>[+362 characters]",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "Ad-hoc-Mitteilung gemäß Art. 17 Marktm[+317 characters]",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> hat beschlossen, das auf[+187 characters]",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "Diese Art des synthetischen Aktienrückk[+330 characters]",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> <em>N.V</em>.\n\nHulsterwe[+236 characters]",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "<em>QIAGEN</em> <em>N.V</em>.: <em>QIAGEN</em> zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück",
"sentiment": null,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "cd816a8b-91a0-457f-9706-68985197a286",
"title": "Sun: El Al leads market higher",
"description": "El Al and Delek Group led the gains today while Ormat and Teva slipped.",
"keywords": "",
"snippet": "The Tel Aviv Stock Exchange rose today. The Tel Aviv 35 Index rose 0.35%, to 2,458.76 points - a new record, the Tel Aviv 125 Index rose 0.16% to 2,492.46 point...",
"url": "https://en.globes.co.il/en/article-sun-el-al-leads-market-higher-1001499223",
"image_url": "https://images.globes.co.il/images/NewGlobes/big_image_800/2018/Globes_Archive_800x392.2018729T150619.jpg",
"language": "en",
"published_at": "2025-01-12T17:54:43.000000Z",
"source": "en.globes.co.il",
"relevance_score": null,
"entities": [
{
"symbol": "TEVA",
"name": "Teva Pharmaceutical Industries Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 47.72372,
"sentiment_score": 0.5473,
"highlights": [
{
"highlight": "(Nasdaq: NICE; TASE:NICE) fell 0.76% and[+261 characters]",
"sentiment": 0.5473,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "0da0a9a4-ee79-4754-bc13-e608b348b579",
"title": "Can Walgreens Boots Alliance Stock Keep Soaring?",
"description": "Shares of Walgreens Boots Alliance (NASDAQ: WBA) rocketed 27.5% higher on Friday, Jan. 10, 2024. Investors of all stripes are wondering whether more gains could be ahead for the beaten-down retail pharmacy chain operator. Income-seeking investors are particularly interested because, despite the recent run-up, shares of Walgreens Boots Alliance have been offering an eye-popping 8.5% dividend yield.",
"keywords": "Walgreens Boots Alliance, retail pharmacy, Walgreens, retail operation, Elizabeth Anderson",
"snippet": "Shares of Walgreens Boots Alliance (NASDAQ: WBA) rocketed 27.5% higher on Friday, Jan. 10, 2024. This isn't nearly enough to recover from a 64% drop the stock n...",
"url": "https://finance.yahoo.com/news/walgreens-boots-alliance-stock-keep-172300783.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/y7D0rTBpVQsOc0rU6.fqag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/bb8f886a629c5c39dff42b799a07636e",
"language": "en",
"published_at": "2025-01-12T17:23:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "WBA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 113.24277,
"sentiment_score": 0.2624,
"highlights": [
{
"highlight": "Shares of <em>Walgreens</em> <em>Boots</[+352 characters]",
"sentiment": 0.5492,
"highlighted_in": "main_text"
},
{
"highlight": "Income-seeking investors are particularl[+320 characters]",
"sentiment": 0.885,
"highlighted_in": "main_text"
},
{
"highlight": "Should you invest $1,000 in <em>Walgreen[+348 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Can <em>Walgreens</em> <em>Boots</em> <e[+79 characters]",
"sentiment": -0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Can <em>Walgreens</em> <em>Boots</em> <em>Alliance</em> Stock Keep Soaring?",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "73cc9864-2835-4f9c-acee-061eb062111c",
"title": "Is Walgreens Boots Alliance, Inc. (WBA) the Best Medical Stock to Buy Under $20?",
"description": "We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Walgreens Boots Alliance, Inc.",
"keywords": "",
"snippet": "We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Walgreens Boots Alliance, Inc. (N...",
"url": "https://www.insidermonkey.com/blog/is-walgreens-boots-alliance-inc-wba-the-best-medical-stock-to-buy-under-20-1422278/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/10/02135417/WBA-insidermonkey-1696269255247.jpg",
"language": "en",
"published_at": "2025-01-12T14:29:17.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "WBA.BA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 171.02368,
"sentiment_score": 0.6458,
"highlights": [
{
"highlight": "In this article, we are going to take a [+242 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+314 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "In its fiscal 2024, <em>Walgreens</em> <[+354 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+354 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (WBA) the Best Medical Stock to Buy Under $20?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "WBA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 189.46513,
"sentiment_score": 0.6404,
"highlights": [
{
"highlight": "In this article, we are going to take a [+251 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+332 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "In its fiscal 2024, <em>Walgreens</em> <[+363 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:WBA</em>) is implementing a [+255 characters]",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:WBA</em>) expects that this [+296 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:WBA</em>) plans to expand it[+312 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (WBA) the Best Medical Stock to Buy Under $20?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "W8A.DE",
"name": "Walgreens Boots Alliance Inc",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 171.0204,
"sentiment_score": 0.6458,
"highlights": [
{
"highlight": "In this article, we are going to take a [+242 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+314 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "In its fiscal 2024, <em>Walgreens</em> <[+354 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+354 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (WBA) the Best Medical Stock to Buy Under $20?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "WBA.MX",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 171.0213,
"sentiment_score": 0.6458,
"highlights": [
{
"highlight": "In this article, we are going to take a [+242 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+314 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "In its fiscal 2024, <em>Walgreens</em> <[+354 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+354 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (WBA) the Best Medical Stock to Buy Under $20?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "0LSZ.L",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 171.01987,
"sentiment_score": 0.6458,
"highlights": [
{
"highlight": "In this article, we are going to take a [+242 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+314 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "In its fiscal 2024, <em>Walgreens</em> <[+354 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+354 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (WBA) the Best Medical Stock to Buy Under $20?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "WGBA34.SA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 171.01654,
"sentiment_score": 0.6458,
"highlights": [
{
"highlight": "In this article, we are going to take a [+242 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+314 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "In its fiscal 2024, <em>Walgreens</em> <[+354 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Al[+354 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (WBA) the Best Medical Stock to Buy Under $20?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
}
]
}
]
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 97,
"sentiment_avg": 0.2890023463304438
}
]
}
Other details
Entity count
- 11,338